CCL2 |
↑ |
Pro-cancer: can promote polarization of M2 macrophages |
Hacke et al. (2010),
Fei et al. (2021)
|
DR5 |
↑ |
Anti-cancer: also known as TRAIL-R2, receptor for TRAIL that promotes cellular apoptosis upon TRAIL binding |
Wu et al. (1997)
|
Fas |
↑ |
Anti-cancer: FasL receptor that promotes extrinsic cellular apoptosis pathways upon ligand binding |
Müller et al. (1998)
|
IRF5 |
↑ |
Anti-cancer: activates the transcription of pro-inflammatory cytokines and mediates apoptosis in cancer cells |
Mori et al. (2002),
Barnes et al. (2003),
Hu et al. (2005),
Honda and Taniguchi (2006),
Yanai et al. (2007),
Couzinet et al. (2008),
Hu and Barnes (2009)
|
IRF9 |
↑ |
Anti-cancer: contributes to p53-mediated upregulation of IFNs |
Muñoz-Fontela et al. (2008)
|
Pro-cancer: may promote cancer cell survival via IL6 & STAT3 activation |
PD-L1 |
↑/↓ |
Pro-cancer: binding to receptor PD-1 suppresses CD8+ T-cell activation |
Cortez et al. (2016),
Thiem et al. (2019),
Costa et al. (2020)
|
PKR |
↑ |
Anti-cancer: supports p53-mediated tumor suppression, mediates inflammasome activation and release of HMGB1 |
Yoon et al. (2009),
Lu et al. (2012)
|
TLRs |
↑ |
Anti-cancer: stimulates pro-inflammatory cytokines in cancer cells & lymphocytes |
Muresan et al. (2020),
Muresan et al. (2020)
|
TRAIL |
↑ |
Anti-cancer: DR4/5 ligand expressed primarily by immune cells |
Kuribayashi et al. (2008)
|
ULBP1/2 |
↑ |
Anti-cancer: enhances NK cell target recognition |
Textor et al. (2011)
|